Azitra (AZTR) Free Cash Flow (2022 - 2026)
Azitra's (AZTR) quarterly Free Cash Flow came in at -$2.5 million in Q1 2026, up 18.87% YoY from -$2.1 million in Q1 2025, and up 13.4% on a QoQ basis from -$2.9 million in Q4 2025.
Azitra (AZTR) Free Cash Flow (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Free Cash Flow data on file, last reported at -$2.5 million in Q1 2026.
- Quarterly Free Cash Flow rose 18.87% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.6 million (down 3.91% YoY) and the FY2025 annual result came in at -$11.2 million, down 10.12% from the prior year.
- Free Cash Flow advanced to -$2.5 million in Q1 2026, from -$2.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.3 million in Q1 2023 to a low of -$3.1 million in Q1 2025.
- A 5-year average of -$2.4 million and a median of -$2.5 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 129.01% — and 2026, when it increased 18.87%.
- Tracing AZTR's Free Cash Flow over 5 years: stood at -$2.2 million in 2022, then retreated by 16.65% to -$2.6 million in 2023, then declined by 1.33% to -$2.6 million in 2024, then fell by 11.27% to -$2.9 million in 2025, then advanced by 13.4% to -$2.5 million in 2026.
- The last three Free Cash Flow figures came in at -$2.5 million (Q1 2026), -$2.9 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | -3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34 Mn |
| Jun 30, 2026 | -3.34 Mn |
| Mar 31, 2026 | -2.49 Mn |
| Mar 31, 2026 | -2.49 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Jun 30, 2025 | -2.83 Mn |
| Jun 30, 2025 | -2.83 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.48 Mn |
| Sep 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Mar 31, 2024 | -3.02 Mn |
| Mar 31, 2024 | -3.02 Mn |